Tbo-filgrastim Clinical Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A timeline chronicling the development history of Teva’s granulocyte colony stimulating factor tbo-filgrastim, previously known as XM-02 and Neutroval.